This represents an increase of 589% compared to the average daily volume of 2,749 call options.
In related news, insider Anthony Mauro sold 10,000 shares of Mylan N.V. stock in a transaction dated Friday, June 9th. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00. Following the transaction, the insider now owns 140,653 shares in the company, valued at $5,626,120. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The Beta for the company stands at 1.29 and its Average True Range (ATR) shows a value of 1.22. Following the completion of the transaction, the president now directly owns 799,855 shares of the company's stock, valued at $31,994,200. The disclosure for this sale can be found here. The stock, as of recent close, has shown weekly downbeat performance of -17.62% which was maintained at -15.72% in 1-month period, and is down -16.67% in this year. Finally, Pzena Investment Management LLC acquired a new stake in shares of Mylan N.V. during the first quarter worth approximately $283,158,000. The fund owned 7,222 shares of the company's stock after buying an additional 2,380 shares during the period. Mylan N.V. The business's revenue for the quarter was up 15.7% compared to the same quarter past year. Morgan Stanley now owns 4,174,499 shares of the company's stock valued at $162,765,000 after buying an additional 1,888,905 shares during the last quarter. Oakworth Capital Inc. raised its position in Mylan N.V.by 30.7% in the first quarter. First Personal Financial Services boosted its stake in shares of Mylan N.V.by 33.2% in the first quarter. Sei Investments Co. now owns 13,870 shares of the company's stock worth $541,000 after buying an additional 134 shares in the last quarter. Bank of Nova Scotia now owns 10,525 shares of the company's stock worth $410,000 after buying an additional 196 shares in the last quarter.
Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its stake in Mylan N.V.by 3.9% in the first quarter. (MYL) traded up 1.15% during midday trading on Thursday, reaching $32.45. The stock has a 50 day moving average of $37.74 and a 200-day moving average of $39.10. Princeton Portfolio Strategies Group Inc Limited Liability Corporation invested 0.77% in Mylan N.V. (NASDAQ:MYL).
Mylan N.V. had a net margin of 4.59% and a return on equity of 23.69%. (NASDAQ:MYL) last posted its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share for the quarter, missing analysts' consensus estimates of $1.18 by $0.08.
Mylan's second-quarter profit and revenue surged, but not as much as Wall Street had expected and the company is taking a more conservative view going forward because of "ongoing challenges and the uncertain USA regulatory environment". Mylan N.V. The company's revenue was up 15.7% compared to the same quarter past year. On average, equities research analysts predict that Mylan N.V. will post $4.86 earnings per share for the current year.
Covering sell-side analysts have recently weighed in on shares of Mylan N.V. (NASDAQ:MYL). It increased, as 3 investors sold Mylan N.V. shares while 2 reduced holdings. The stock of Mylan N.V. (NASDAQ:MYL) earned "Hold" rating by Zacks on Thursday, August 27. Mylan N.V. also was the recipient of unusually large options trading on Monday.
Pakistani Ousted Prime Minister Starts Rally Procession to Hometown
Speaking on the eve of his departure, Sharif said that Pakistan had only ever seen "a crippled democracy". Sharif also announced that he respects the decision despite serious reservations.
And, for generic Copaxone, the company still has a target action date of mid-September, Malik said. Cowen & Co downgraded the shares of MYL in report on Monday, July 27 to "Market Perform" rating. Finally, Cantor Fitzgerald initiated coverage on shares of Mylan N.V.in a research report on Friday, June 16th. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the company's stock. Mylan N.V. (NASDAQ:MYL) has declined 7.73% since August 10, 2016 and is downtrending.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of worldwide copyright & trademark legislation.
Continued delays in launching the two high-profile generics, however, means there is little to distract investors from a tightening price environment in the U.S. Mylan expects prices to decline by mid-single digits globally and by high-single digits in the U.S.
Plans to divest Medis, an Icelandic unit that develops generics for other companies, and its respiratory products would follow other pending disposals including its women's health business and European oncology and pain treatments.
The company faces regulatory uncertainty in the rollout of two new products: generic versions of Teva Pharmaceutical Industries' Copaxone, used to treat multiple sclerosis, and GlaxoSmithKline's Advair, used to treat asthma and COPD.